Dr. Lucy Potter, MD

Dr. Potter practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Potter's NPI, 1245868660, was assigned on March 31, 2020. Dr. Potter graduated from Baylor College Of Medicine in 2017. Dr. Potter holds Texas license T7004.

Dr. Potter's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Potter's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Potter practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Potter's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Potter is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Potter's licenses on file in 10 states: Texas, Florida, Arizona, Washington, Georgia, Louisiana, Mississippi, Oklahoma, Alabama and Nevada.

Dmand AI lists chronic anemia, chronic hypertension, coronary artery disease, heart valve disorders, neuropathy and varicose veins among the conditions Dr. Potter treats.

CMS data shows 385 Medicare services from Dr. Potter across 7 procedure codes in 2024, for 308 Medicare patients. Medicare paid $39,314 for them.

CMS counts 308 Medicare patients who saw Dr. Potter in 2024. The largest group is 65 to 74, with 183 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Potter's median patient age at 69, with 53% women.

In 2024, Dr. Potter wrote 387 Medicare Part D claims for 98 patients. 81% of them were for generic drugs. CMS names the drug for 230 of them, across 12 drugs with 11 or more claims each, at $24,601 in total drug cost. In 2023, CMS named 209 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Potter for performance year 2024, reported as part of a group. Dr. Potter accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Potter as offering telehealth.

Dmand AI links 4 papers to Dr. Potter, published from 2014 to 2019. The most frequent topics are Neoadjuvant Therapy and Pancreatic Neoplasms. Dr. Potter has published most often in Am J Clin Oncol. Dr. Potter's most frequent co-authors are Maen Abdelrahim, MD, Kirk E. Heyne, MD and Ashish Saharia, MD.

CMS Open Payments shows 1 general payment to Dr. Potter from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Sandoz Inc. paid the most, $80.

Dmand AI lists 1 award for Dr. Potter, most recently Resident of the Year in 2023.

Dr. Potter graduated from Baylor College Of Medicine in 2017. Dr. Potter is a member of ACP, AMA and ASCO.

Dr. Potter is in network with 6 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.